The estimated Net Worth of Wilfred Ethree Arch Managem... is at least 19.9 百万$ dollars as of 10 September 2015. Wilfred Managem owns over 120,000 units of Concert Pharmaceuticals Inc stock worth over 6,227$ and over the last 9 years Wilfred sold CNCE stock worth over 19,920,420$.
Wilfred has made over 6 trades of the Concert Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Wilfred sold 68,854 units of CNCE stock worth 1,378,457$ on 14 December 2015.
The largest trade Wilfred's ever made was selling 760,000 units of Concert Pharmaceuticals Inc stock on 14 August 2015 worth over 12,015,600$. On average, Wilfred trades about 201,285 units every 21 days since 2015. As of 10 September 2015 Wilfred still owns at least 744 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Wilfred Managem stock trades at the bottom of the page.
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over 69,766,120$ worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth 25,219,472$ . The most active insiders traders include Plc Gsk、Associates Gp Llcqvt Fund V...、Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of 447,820$. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth 50,380$.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: